Research programme: antibody therapeutics - F-star

Drug Profile

Research programme: antibody therapeutics - F-star

Alternative Names: Fcab - F-star; Fcab antibody fragments - F-star; FS 101; FS 117; FS 120; FS 17; FS 18; FS 20; FS 22; mAb²TM

Latest Information Update: 13 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator f-star
  • Class Antineoplastics; Bispecific antibodies; Immunoconjugates
  • Mechanism of Action Apoptosis stimulants; CD223 antigen inhibitors; Checkpoint kinase inhibitors; Epidermal growth factor inhibitors; ERBB 2 receptor antagonists; Hepatocyte growth factor inhibitors; Programmed cell death-1 ligand-1inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 05 Mar 2018 F-star Delta Limited plans a phase I trial for solid tumours and haematological malignancies (Late stage disease, Second line therapy or greater, Metastatic disease. Inoperable/unresectable), in April 2018 (NCT03440437)
  • 09 Oct 2017 Heidelberg Pharma is now called Heidelberg Pharma Research
  • 05 Aug 2016 F-star and Ligand Pharmaceuticals enter into an agreement to discover human mono and bi-specific antibodies utilising Ligand's OmniAb platform, before August 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top